Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma.

Molfino NA, Kuna P, Leff JA, Oh CK, Singh D, Chernow M, Sutton B, Yarranton G.

BMJ Open. 2016 Jan 6;6(1):e007709. doi: 10.1136/bmjopen-2015-007709.

2.

Discriminating sputum-eosinophilic asthma: Accuracy of cutoffs in blood eosinophil measurements versus a composite index, ELEN.

Khatry DB, Gossage DL, Geba GP, Parker JM, Jarjour NN, Busse WW, Molfino NA.

J Allergy Clin Immunol. 2015 Sep;136(3):812-814.e2. doi: 10.1016/j.jaci.2015.03.006. Epub 2015 Apr 23. No abstract available.

PMID:
25913197
3.

The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study.

Schmidt SA, Johansen MB, Olsen M, Xu X, Parker JM, Molfino NA, Lash TL, Sørensen HT, Christiansen CF.

BMJ Open. 2014 Dec 19;4(12):e006720. doi: 10.1136/bmjopen-2014-006720.

4.

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma.

Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, Fiening JP, Kim K, Molfino NA.

Am J Emerg Med. 2015 Jan;33(1):14-20. doi: 10.1016/j.ajem.2014.09.036. Epub 2014 Oct 5.

PMID:
25445859
5.

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG.

Lancet Respir Med. 2014 Nov;2(11):879-890. doi: 10.1016/S2213-2600(14)70201-2. Epub 2014 Oct 8.

PMID:
25306557
6.

A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma.

Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA.

Respir Res. 2013 Sep 19;14:93. doi: 10.1186/1465-9921-14-93.

7.

Recent therapeutic breakthroughs in respiratory medicine.

Molfino NA.

Expert Rev Respir Med. 2013 Aug;7(4):331-3. doi: 10.1586/17476348.2013.814388. No abstract available.

PMID:
23964623
8.

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.

Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA.

J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5. doi: 10.1016/j.jaci.2013.05.020. Epub 2013 Jul 16. Erratum in: J Allergy Clin Immunol. 2014 Apr;133(4):1232.

9.

Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based Danish cohort study.

Johannesdottir SA, Christiansen CF, Johansen MB, Olsen M, Xu X, Parker JM, Molfino NA, Lash TL, Fryzek JP.

J Med Econ. 2013 Jul;16(7):897-906. doi: 10.3111/13696998.2013.800525. Epub 2013 May 23.

PMID:
23621504
10.

Challenge models to assess new therapies in chronic obstructive pulmonary disease.

van der Merwe R, Molfino NA.

Int J Chron Obstruct Pulmon Dis. 2012;7:597-605. doi: 10.2147/COPD.S30664. Epub 2012 Sep 13. Review.

11.

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma.

Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, Molfino NA.

Eur Respir J. 2013 Feb;41(2):330-8. doi: 10.1183/09031936.00223411. Epub 2012 Jun 27.

12.

Targeting of eosinophils in asthma.

Molfino NA.

Expert Opin Biol Ther. 2012 Jul;12(7):807-9. doi: 10.1517/14712598.2012.674938. Epub 2012 Apr 16.

PMID:
22500988
13.

Smoking and idiopathic pulmonary fibrosis.

Oh CK, Murray LA, Molfino NA.

Pulm Med. 2012;2012:808260. doi: 10.1155/2012/808260. Epub 2012 Feb 19.

14.

Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.

Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP.

Clin Exp Allergy. 2012 May;42(5):712-37. doi: 10.1111/j.1365-2222.2011.03854.x. Epub 2011 Sep 23. Review.

PMID:
22092535
15.

Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma.

Oh CK, Raible D, Geba GP, Molfino NA.

Inflamm Allergy Drug Targets. 2011 Jun;10(3):180-6. Review.

PMID:
21428906
16.

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.

Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Molfino NA; MEDI-528 Clinical Trials Group.

BMC Pulm Med. 2011 Feb 28;11:14. doi: 10.1186/1471-2466-11-14.

17.

Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma.

Oh CK, Geba GP, Molfino N.

Eur Respir Rev. 2010 Mar;19(115):46-54. doi: 10.1183/09059180.00007609. Review.

18.

Brain magnetic resonance imaging in adults with asthma.

Parker J, Wolansky LJ, Khatry D, Geba GP, Molfino NA.

Contemp Clin Trials. 2011 Jan;32(1):86-9. doi: 10.1016/j.cct.2010.09.006. Epub 2010 Sep 18.

PMID:
20854931
19.

An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.

Oh CK, Faggioni R, Jin F, Roskos LK, Wang B, Birrell C, Wilson R, Molfino NA.

Br J Clin Pharmacol. 2010 Jun;69(6):645-55. doi: 10.1111/j.1365-2125.2010.03647.x.

20.

MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.

Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ.

J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2. doi: 10.1016/j.jaci.2010.04.004.

PMID:
20513525
21.

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.

Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, Geba GP, Molfino NA.

J Allergy Clin Immunol. 2010 Jun;125(6):1237-1244.e2. doi: 10.1016/j.jaci.2010.04.005.

PMID:
20513521
22.

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma.

Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A.

BMC Pulm Med. 2010 Jan 8;10:3. doi: 10.1186/1471-2466-10-3.

23.

Increased vagal airway tone in fatal asthma.

Molfino NA.

Med Hypotheses. 2010 Mar;74(3):521-3. doi: 10.1016/j.mehy.2009.10.002. Epub 2009 Nov 10.

PMID:
19906493
24.

Gene-environment interactions in chronic obstructive pulmonary disease.

Molfino NA, Coyle AJ.

Int J Chron Obstruct Pulmon Dis. 2008;3(3):491-7.

25.

A meta-analysis on the efficacy of oral theophylline in patients with stable COPD.

Molfino NA, Zhang P.

Int J Chron Obstruct Pulmon Dis. 2006;1(3):261-6.

26.

Genetic predisposition to accelerated decline of lung function in COPD.

Molfino NA.

Int J Chron Obstruct Pulmon Dis. 2007;2(2):117-9. Review.

27.

Current thinking on genetics of chronic obstructive pulmonary disease.

Molfino NA.

Curr Opin Pulm Med. 2007 Mar;13(2):107-13. Review.

PMID:
17255800
28.

Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies.

Molfino NA, Jeffery PK.

Pulm Pharmacol Ther. 2007;20(5):462-72. Epub 2006 May 6. Review.

PMID:
16798034
29.

Drugs in clinical development for chronic obstructive pulmonary disease.

Molfino NA.

Respiration. 2005 Jan-Feb;72(1):105-12. Review.

PMID:
15753645
30.

[Treatment of patients with chronic obstructive pulmonary disease (COPD) by primary care physicians].

Molfino NA.

Medicina (B Aires). 2004;64(5):445-54. Review. Spanish.

PMID:
15560549
31.

Trends in pharmacotherapy for chronic airflow limitation in Argentina: 1992-2002.

Molfino NA.

Medicina (B Aires). 2004;64(5):407-12.

PMID:
15560541
32.

[Lung function evolution and respiratory symptoms].

Molfino NA.

Arch Bronconeumol. 2004 Oct;40(10):429-30. Spanish. No abstract available.

33.

Genetics of COPD.

Molfino NA.

Chest. 2004 May;125(5):1929-40. Review.

PMID:
15136409
34.

Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.

De Feo LG, Schottlender J, Martelli NA, Molfino NA.

Muscle Nerve. 2002 Jul;26(1):31-6.

PMID:
12115946
35.

Eradication of multiple myeloma and breast cancer cells by TH9402-mediated photodynamic therapy: implication for clinical ex vivo purging of autologous stem cell transplants.

Brasseur N, Ménard I, Forget A, el Jastimi R, Hamel R, Molfino NA, van Lier JE.

Photochem Photobiol. 2000 Dec;72(6):780-7.

PMID:
11140266
36.

Risk factors versus mechanisms of death in subjects with asthma.

Molfino NA.

Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1355-6. No abstract available.

PMID:
10336297
37.

Effect of inhaled furosemide in acute asthma.

Pendino JC, Nannini LJ, Chapman KR, Slutsky A, Molfino NA.

J Asthma. 1998;35(1):89-93.

PMID:
9513587
38.
39.

Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma.

Newhouse MT, Chapman KR, McCallum AL, Abboud RT, Bowie DM, Hodder RV, Paré PD, Mesic-Fuchs H, Molfino NA.

Chest. 1996 Sep;110(3):595-603.

PMID:
8797398
40.

Tracheobronchial constriction in asthmatics induced by isocapnic hyperventilation with dry cold air.

Julià-Serdà G, Molfino NA, Califaretti N, Hoffstein V, Zamel N.

Chest. 1996 Aug;110(2):404-10.

PMID:
8697842
41.

Analysis of the T cell receptor Vgamma region gene repertoire in bronchoalveolar lavage (BAL) and peripheral blood of atopic asthmatics and healthy subjects.

Molfino NA, Doherty PJ, Suurmann IL, Yang SX, Kesten S, Chapman KR, Slutsky AS.

Clin Exp Immunol. 1996 Apr;104(1):144-53.

42.

The effect of pre-exposure to 0.12 ppm of ozone on exercise-induced asthma.

Fernandes AL, Molfino NA, McClean PA, Silverman F, Tarlo S, Raizenne M, Slutsky AS, Zamel N.

Chest. 1994 Oct;106(4):1077-82.

PMID:
7924476
43.

Near-fatal asthma.

Molfino NA, Slutsky AS.

Eur Respir J. 1994 May;7(5):981-90. Review.

44.

[Treatment of asthma in Argentina].

Molfino NA.

Medicina (B Aires). 1994;54(2):179-82. Spanish. No abstract available.

PMID:
7997140
45.

Trends in pharmacotherapy for chronic airflow limitation in Argentina: 1983-1990.

Molfino NA, Nannini LJ Jr, Chapman KR, Slutsky AS.

Medicina (B Aires). 1994;54(2):103-9.

PMID:
7997125
46.

Assessment of airway tone in asthma. Comparison between double lung transplant patients and healthy subjects.

Molfino NA, Slutsky AS, Julià-Serdà G, Hoffstein V, Szalai JP, Chapman KR, Rebuck AS, Zamel N.

Am Rev Respir Dis. 1993 Nov;148(5):1238-43.

PMID:
8239160
47.

Tracheobronchial dilation during isocapnic hypoxia in conscious humans.

Julià-Serdà G, Molfino NA, Furlott HG, McClean PA, Rebuck AS, Hoffstein V, Slutsky AS, Zamel N, Chapman KR.

J Appl Physiol (1985). 1993 Oct;75(4):1728-33.

PMID:
8282626
48.

Heterogeneous airway tone in asthmatic subjects.

Julia-Serda G, Molfino NA, Chapman KR, McClean PA, Zamel N, Slutsky AS, Hoffstein V.

J Appl Physiol (1985). 1992 Dec;73(6):2328-32.

PMID:
1490940
49.

[Echogram of the upper airway].

Julià-Serdà G, Molfino NA, Zamel N.

Med Clin (Barc). 1992 Oct 10;99(11):425-9. Review. Spanish. No abstract available.

PMID:
1469941
50.

Changes in cross-sectional airway areas induced by methacholine, histamine, and LTC4 in asthmatic subjects.

Molfino NA, Slutsky AS, Hoffstein V, McClean PA, Rebuck AS, Drazen JM, Zamel N.

Am Rev Respir Dis. 1992 Sep;146(3):577-80.

PMID:
1519831

Supplemental Content

Loading ...
Support Center